19 October-1 December 2020
The 51st Union World Conference On Lung Health


All Sessions
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Channel 7
OA-17-Safety first: side effects of old and new drugs
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-17-Safety first: side effects of old and new drugs
*Please scroll down for more information*

12:30 - 12:35: Introduction

12:35 - 12:43: OA-17-605-22-Audiometry outcomes during and after drug-resistant TB treatment with a kanamycin-containing drug-regimen: drug-resistant TB patients assessed in three rural districts of Masvingo Zimbabwe The abstract focuses on the ototoxic effects of a kanamycin-containing regimen on drug-resistant (DR-TB) patients managed in rural Zimbabwe without previous access to audiometry monitoring. Results show the importance of screening for drug side-effects during, as well as after, stopping the drug.

Cordelia Kunzekwenyika

12:43 - 12:51: OA-17-606-22-Validation study comparing tablet-based and conventional audiometry results in stage 2 of the STREAM trial Due to limited access to conventional audiometry testing in many high TB burden countries, tablet-based audiometry was used to monitor and evaluate for changes in hearing among multidrug-resistant tuberculosis trial participants. This validation study investigates the accuracy of tablet-based audiometry compared to conventional audiometry in stage 2 of the STREAM Trial.

Ishmael Qawiy

12:51 - 12:59: OA-17-607-22-Safety and efficacy of a shorter TB treatment: time to sputum culture positivity as a surrogate marker of bacterial load in an radomised control study of high-dose rifampicin and pyrazinamide Tuberculosis (TB) treatment is long, posing a risk of poor treatment adherence. In this randomised phase II study, we aim to investigate a strategy to shorten TB treatment by exploring safety, drug exposure and efficacy of a high-dose rifampicin/pyrazinamide regimen on early bactericidal activity using time to sputum culture positivity (TTP).

David Ekqvist

12:59 - 13:07: OA-17-608-22-Predictive analyses of QT prolongation from ECG monitoring in STREAM stage 1 The STREAM stage 1 trial investigated a short nine-month regimen for the treatment of multidrug-resistant tuberculosis, which included high-dose moxifloxacin and clofazimine, both of which can lead to QT prolongation. We analysed whether assessment of QT interval early on in treatment could be used to identify patients requiring more intensive QT monitoring.

Gareth Hughes

13:07 - 13:15: OA-17-609-22-A study to determine the frequency of QT interval prolongation in people treated with bedaquiline for drug-resistant TB Bedaquiline (BDQ) is a recent addition to the drug-resistant tuberculosis (DR-TB) armamentarium. There is a black-box warning of arrhythmias and sudden death associated with BDQ therapy. This retrospective study aimed to determine the incidence of QTc prolongation and cardiac events in patients receiving BDQ DR-TB therapy under routine conditions.

Sharon Isralls

13:15 - 13:23: OA-17-610-22-Pretomanid added to bedaquiline and linezolid for patients with extensively-drug resistant TB and multidrug-resistant TB treatment failure or intolerance: a comparison of prospective cohorts The Nix-TB study, evaluating the treatment of 109 patients with highly resistant TB with the oral 3-drug regimen (bedaquiline, pretomanid and linezolid; BPaL) for six-nine months, is compared to a cohort of contemporaneous patients, in South Africa, receiving regimens that included bedaquiline and linezolid, but not pretomanid.

Suzette Oelofse

13:23 - 13:31: OA-17-611-22-Moxifloxacin pharmacokinetics and cardiac safety in children with multidrug-resistant TB In this work, we characterise moxifloxacin pharmacokinetics and the exposure-response relationship with QT-interval prolongation in children 0-17 years. These results are from two observational pharmacokinetic and safety studies and provide important information regarding moxifloxacin use in young (<7 years) children and insight on optimal dosing.

Kendra K Radtke

13:31 - 13:50: Q&A

Processing. Please wait.